Does treatment with sodium-glucose co-transporter-2 inhibitors have an effect on sleep quality, quality of life, and anxiety levels in people with Type 2 diabetes mellitus?
TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.51, sa.2, ss.735-742, 2021 (SCI-Expanded, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 51 Sayı: 2
- Basım Tarihi: 2021
- Doi Numarası: 10.3906/sag-2008-37
- Dergi Adı: TURKISH JOURNAL OF MEDICAL SCIENCES
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.735-742
- Anahtar Kelimeler: Anxiety, sleep quality, quality of life, sodium-glucose co-transporter 2 inhibitor, INADEQUATE GLYCEMIC CONTROL, SGLT2 INHIBITORS, DOUBLE-BLIND, DAPAGLIFLOZIN, PREVALENCE, HEALTH, ADULTS, HYPOGLYCEMIA, ASSOCIATION, INFECTIONS
- İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet
Özet
Background/aim: To evaluate the impact of treatment with sodium-glucose co-transporter-2 (SGLT2) Inhibitors on quality of life (QoL), sleep quality (SQ), and anxiety levels in patients with Type 2 diabetes mellitus (T2DM).